TNFSF9 and neoplasm: It would have been informative to demonstrate the enhanced Akt-driven glycolysis as the basis of the higher potency in vivo, e.g., in a murine tumor model, by genetic manipulation of key glycolytic enzymes (e.g., HK2) specifically in CD137L-DCs.